• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is NovoCure (NVCR) Below Fair Value Following The FDA Optune Mya Setback?

    Simply Wall St·11/12/2026 07:25:09
    Listen to the news

    NovoCure (NVCR) drew fresh attention after the FDA issued a Not Approvable Letter for its Optune Mya device for brain metastases in non small cell lung cancer, citing uncertainty around clinical benefit.

    The FDA setback has landed after a tough stretch for NovoCure’s stock, with the 7 day share price return down 17.93% and the 30 day share price return down 18.55%, while the 1 year total shareholder return is up 5.55%. This suggests that shorter term momentum is fading even as the longer term picture reflects a modest recovery from much steeper multi year losses.

    Spot fresh ideas reacting to clinical and regulatory catalysts by scanning 37 healthcare AI stocks that may be setting up for their next major move.

    After this sharp reset on the Optune Mya news, the debate turns to NovoCure’s US$11.99 share price. Is most of the recovery already in the rear-view mirror, or is meaningful upside still ahead?

    Most Popular Narrative: 55% Undervalued

    NovoCure’s analyst consensus Narrative on Simply Wall St places fair value at $26.86, compared to the recent $11.99 close. This highlights a wide gap that the market is pricing in despite the recent FDA setback.

    Validation of TTFields therapy in multiple new indications, such as pancreatic cancer and brain metastases from non small cell lung cancer, continues to progress through programs like Optune Pax and Optune Mya. This could widen NovoCure’s addressable patient pool and support future revenue growth as new approvals and launches are executed.

    See why 13 investors see NovoCure as 55% undervalued.

    Result: Fair Value of $26.86 (UNDERVALUED)

    Still, the NovoCure story can break if Optune Pax adoption keeps slipping or if ongoing legal investigations extend GAAP losses for a longer period than analysts expect.

    Find out about the key risks to this NovoCure narrative.

    Next Steps

    The debate around NovoCure is clearly split, which is exactly when it helps to move fast and stress test the numbers yourself. To see what the current optimism is about, review the 3 key rewards.

    Looking for more NovoCure style investment ideas?

    If NovoCure has your attention, do not stop here. Broaden your watchlist with fresh ideas that could react significantly when sentiment or fundamentals shift.